CORE-008 Cohort B Evaluates Cretostimogene in BCG-Exposed Non-Muscle Invasive Bladder Cancer - Trinity Bivalacqua - UroToday
CORE-008 Cohort B Evaluates Cretostimogene in BCG-Exposed Non-Muscle Invasive Bladder Cancer - Trinity Bivalacqua UroToday
Bladder Cancer News
Jonathan Anker, MD, highlights response-guided bladder preservation strategy in MIBC - Urology Times
Jonathan Anker, MD, highlights response-guided bladder preservation strategy in MIBC Urology Times
Clinical Practice Updates: Navigating the New Standard of Care in Bladder Cancer - Oncology Nursing News
Clinical Practice Updates: Navigating the New Standard of Care in Bladder Cancer Oncology Nursing News
enGene Rebrands as enGene Therapeutics Ahead of Planned Bladder Cancer Gene Therapy Filing - TipRanks
enGene Rebrands as enGene Therapeutics Ahead of Planned Bladder Cancer Gene Therapy Filing TipRanks
INLEXZO™ (gemcitabine intravesical system) Assigned Permanent Billing Code, Supporting Access for Patients with Certain Bladder Cancers - Johnson & Johnson
INLEXZO™ (gemcitabine intravesical system) Assigned Permanent Billing Code, Supporting Access for Patients with Certain Bladder Cancers Johnson & Johnson
Expanding Options for Cisplatin-Ineligible Bladder Cancer - Targeted Oncology
Expanding Options for Cisplatin-Ineligible Bladder Cancer Targeted Oncology
Tumor “Waste” Metabolite Succinate Rewires Bladder Muscle to Build Metastatic Blood-Vessel Niches | Newswise - Newswise
Tumor “Waste” Metabolite Succinate Rewires Bladder Muscle to Build Metastatic Blood-Vessel Niches | Newswise Newswise
Alan Davies reveals key symptom that led to bladder cancer diagnosis - The Independent
Alan Davies reveals key symptom that led to bladder cancer diagnosis The Independent
Optimizing treatment with intravesical drug-releasing systems in NMIBC - Urology Times
Optimizing treatment with intravesical drug-releasing systems in NMIBC Urology Times
Study finds link between colorblindness and death from bladder cancer - Stanford Medicine
Study finds link between colorblindness and death from bladder cancer Stanford Medicine
Blood Test Predicts Which Bladder Cancer Patients May Safely Skip Surgery - Fox Chase Cancer Center
Blood Test Predicts Which Bladder Cancer Patients May Safely Skip Surgery Fox Chase Cancer Center
Neoadjuvant Systemic Therapy in Kidney and Bladder Cancer: Current Evidence and Emerging Paradigms - ASCO Publications
Neoadjuvant Systemic Therapy in Kidney and Bladder Cancer: Current Evidence and Emerging Paradigms ASCO Publications
ImmunityBio responds to FDA scrutiny over Anktiva promotional claims with new protocols - Fierce Pharma
ImmunityBio responds to FDA scrutiny over Anktiva promotional claims with new protocols Fierce Pharma
ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer - NEJM
ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer NEJM
A Two-Decade Journey of Buschke-Löwenstein Tumor Without Malignant Transformation: Clinical Insights and Management - Cureus
A Two-Decade Journey of Buschke-Löwenstein Tumor Without Malignant Transformation: Clinical Insights and Management Cureus
New drug developed at UC Davis offers hope to bladder cancer patients - University of California - Davis Health
New drug developed at UC Davis offers hope to bladder cancer patients University of California - Davis Health
Bladder Preservation After Neoadjuvant EV+Pembrolizumab - Bogdana Schmidt & Fernando Maluf - UroToday
Bladder Preservation After Neoadjuvant EV+Pembrolizumab - Bogdana Schmidt & Fernando Maluf UroToday
Can ctDNA Predict Metastatic Risk in Bladder Cancer? - Oncology News Central
Can ctDNA Predict Metastatic Risk in Bladder Cancer? Oncology News Central
Alexandra Drakaki, MD, on misdiagnosis of bladder cancer in women - Urology Times
Alexandra Drakaki, MD, on misdiagnosis of bladder cancer in women Urology Times
FDA issues warning letter to ImmunityBio over misleading promotion of NAI - Urology Times
FDA issues warning letter to ImmunityBio over misleading promotion of NAI Urology Times
Hypoxia-inducible factor 1α exerts dual roles in bladder cancer progression through TIMP3-mediated regulation of angiogenesis and invasion | Scientific Reports - Nature
Hypoxia-inducible factor 1α exerts dual roles in bladder cancer progression through TIMP3-mediated regulation of angiogenesis and invasion | Scientific Reports Nature
Bladder Cancer Therapy Enfortumab Vedotin (Padcev) Approved by FDA for More Patients - Memorial Sloan Kettering Cancer Center
Bladder Cancer Therapy Enfortumab Vedotin (Padcev) Approved by FDA for More Patients Memorial Sloan Kettering Cancer Center
Advances in the management of localized bladder cancers - Nature
Advances in the management of localized bladder cancers Nature
USC study suggests type 1 diabetes may significantly raise bladder cancer risk - Keck School of Medicine of USC
USC study suggests type 1 diabetes may significantly raise bladder cancer risk Keck School of Medicine of USC
enGene Therapeutics Announces Name Change Ahead of Potential 2027 Approval - National Today
enGene Therapeutics Announces Name Change Ahead of Potential 2027 Approval National Today
enGene Announces Name Change to enGene Therapeutics Inc. - PharmiWeb.com
enGene Announces Name Change to enGene Therapeutics Inc. PharmiWeb.com
New Survey Reveals Non-Muscle Invasive Bladder Cancer Patients Seek More Care Conversations - ImmunityBio
New Survey Reveals Non-Muscle Invasive Bladder Cancer Patients Seek More Care Conversations ImmunityBio
A multi-modal approach for decision making in bladder cancer - Nature
A multi-modal approach for decision making in bladder cancer Nature
Mayo Clinic expert highlights improved survival in muscle-invasive bladder cancer and kidney cancer - Mayo Clinic News Network
Mayo Clinic expert highlights improved survival in muscle-invasive bladder cancer and kidney cancer Mayo Clinic News Network
Artificial intelligence-assisted diagnosis and histopathological grading of bladder cancer: current status, challenges, and future directions - Frontiers
Artificial intelligence-assisted diagnosis and histopathological grading of bladder cancer: current status, challenges, and future directions Frontiers
Bladder Cancer: What You Need to Know - University of Colorado Anschutz
Bladder Cancer: What You Need to Know University of Colorado Anschutz
HER2 in Bladder Cancer: A Frequent but Complex and Dynamic Biomarker - Daniele Raggi - UroToday
HER2 in Bladder Cancer: A Frequent but Complex and Dynamic Biomarker - Daniele Raggi UroToday
Outcomes of sequential therapy for advanced upper tract urothelial cancer and bladder cancer - Nature
Outcomes of sequential therapy for advanced upper tract urothelial cancer and bladder cancer Nature
Top 10 Urology Times bladder cancer articles of 2025 - Urology Times
Top 10 Urology Times bladder cancer articles of 2025 Urology Times
Groundbreaking Advances for Patients with Muscle-Invasive Bladder Cancer and More to Come - Memorial Sloan Kettering Cancer Center
Groundbreaking Advances for Patients with Muscle-Invasive Bladder Cancer and More to Come Memorial Sloan Kettering Cancer Center
Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial - The Lancet
Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial The Lancet
Johnson & Johnson (JNJ) Advances Bladder Cancer Treatment with 89% Response Rate - Yahoo Finance
Johnson & Johnson (JNJ) Advances Bladder Cancer Treatment with 89% Response Rate Yahoo Finance
Bladder Cancer Symptoms and What You Need to Know About Treatment - University of Rochester Medical Center
Bladder Cancer Symptoms and What You Need to Know About Treatment University of Rochester Medical Center
Low-grade non-muscle-invasive bladder cancer: molecular landscape, treatment strategies and emerging therapies - Nature
Low-grade non-muscle-invasive bladder cancer: molecular landscape, treatment strategies and emerging therapies Nature
New Drug-Releasing System Eliminates Bladder Cancer in Over 80 of Patients in a Phase II Trial - The ASCO Post
New Drug-Releasing System Eliminates Bladder Cancer in Over 80 of Patients in a Phase II Trial The ASCO Post